EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study

Ogur Karhan, Serdar İleri, Zuhat Urakçı, Hayati Arvas, Delyadıl Karakaş Kılıç, Yasin Sezgin, Berrak Merit Erçek, Sezai Tunç

Oncology · 2024

DOI: 10.1159/000542693 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology, 2024. Verfasst von Ogur Karhan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Harran University Hospital, University of Harran, Şanliurfa, Turkey. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Proton Pump Inhibitors. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Conflicting evidence exists regarding the concurrent use of cyclin-dependent kinase (CDK) 4/6 inhibitors and proton pump inhibitors (PPIs) in the treatment of breast cancer. This study aimed to investigate whether PPI use interferes with the efficacy of CDK4/6 inhibitors.

Methods

This retrospective, multicenter, real-world study included 205 patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Patient data were collected from January 2020 to August 2023. Patients who received either ribociclib or palbociclib, with or without a PPI, were included. Median progression-free survival (mPFS) was estimated using the Kaplan-Meier method, and factors associated with mPFS were analyzed using Cox regression.

Results

Among the patients, 100 received palbociclib and 105 received ribociclib. In the palbociclib group, 40 patients (40%) used a PPI, and 60 (60%) did not. The mPFS was 16.1 months for patients with a PPI versus 22.2 months for those without (p = 0.26). In the ribociclib group, 44 patients used a PPI and 61 did not use a PPI. The median PFS was comparable between patients receiving PPIs and those not receiving PPIs (19.3 months and 20.7 months, respectively). Poor PFS was associated with liver metastasis, brain metastasis, and high Ki-67.

Conclusion

Concomitant use of PPIs with ribociclib or palbociclib did not affect the efficacy of either CDK4/6 inhibitor. PPIs can be administered alongside these medications when clinically indicated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Proton Pump InhibitorsProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesMiddle AgedAgedAminopyridinesPiperazinesPurinesAdultProgression-Free SurvivalPyridinesAged, 80 and overNeoplasm MetastasisReceptors, EstrogenErb-b2 Receptor Tyrosine KinasesReceptors, Progesterone

Stichwörter der Autor:innen

Breast cancerDrug interactionsPalbociclibProton pump inhibitorsRibociclib

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Proton Pump InhibitorsProtein Kinase InhibitorsAminopyridinesPiperazinesPurinesPyridinesReceptors, EstrogenErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Medical Oncology, Harran University Hospital, University of Harran, Şanliurfa, Turkey.
  • Department of Medical Oncology, Gazi Yasargil Research and Training Hospital, Diyarbakir, Turkey.
  • Department of Medical Oncology, Dicle University Hospital, University of Dicle, Diyarbakir, Turkey.
  • Department of Medical Oncology, Yuzuncu Yıl University Hospital, University of Yuzuncu Yıl, Van, Turkey.
  • Department of Medical Oncology, Mehmet Akif Inan Research and Training Hospital, Şanlıurfa, Turkey.

Zitieren

APA

Karhan, O., İleri, S., Urakçı, Z., Arvas, H., Kılıç, D. K., Sezgin, Y., Erçek, B. M., & Tunç, S. (2024). Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study. Oncology. https://doi.org/10.1159/000542693

Vancouver

Karhan O, İleri S, Urakçı Z, Arvas H, Kılıç DK, Sezgin Y, et al. Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study. Oncology. 2024. doi:10.1159/000542693

BibTeX
@article{Karhan2024,
  author = {Karhan, Ogur and İleri, Serdar and Urakçı, Zuhat and Arvas, Hayati and Kılıç, Delyadıl Karakaş and Sezgin, Yasin and Erçek, Berrak Merit and Tunç, Sezai},
  title = {Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000542693}
}
Kostenlos starten →